Pliant Therapeutics, Inc.
NASDAQ:PLRXBiotechnology
-$0.04 today
- Market cap
- $50.14M
- Beta
- 1.21
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$1.83
Volume 0.15M
Average 0.49M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Pliant Therapeutics, Inc.
NASDAQ:PLRX
Intrinsic Alpha fair value
Locked
Current Price
$0.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Ovid Therapeutics Inc. NASDAQ:OVID | $496.06M | $2.54 | Not rated | -7.1 | +91.80% |
Artiva Biotherapeutics, Inc. NASDAQ:ARTV | $204.85M | $4.19 | Not rated | -2.7 | +20.82% |
Whitehawk Therapeutics Inc NASDAQ:WHWK | $184.71M | $3.24 | Not rated | -2.6 | +56.78% |
MacroGenics, Inc. NASDAQ:MGNX | $152.88M | $2.40 | Not rated | -3.6 | +44.53% |
Sutro Biopharma, Inc. NASDAQ:STRO | $150.89M | $9.10 | Not rated | -0.0 | +2.95% |
Zentalis Pharmaceuticals, Inc. NASDAQ:ZNTL | $139.53M | $1.96 | Not rated | -2.1 | +4.62% |
Coya Therapeutics, Inc. NASDAQ:COYA | $84.68M | $3.61 | Not rated | -3.9 | -50.17% |
Clene Inc. NASDAQ:CLNN | $54.44M | $3.83 | Not rated | -2.1 | -60.05% |
Fractyl Health, Inc. Common Stock NASDAQ:GUTS | $12.95M | $0.98 | Not rated | -0.6 | +222.48% |
Continue the stock analysis
Jump to another research area for this company.